Tarsus Pharmaceuticals, Inc. (TARS) Form 10-Q — Nov 3, 2026
The quarter also included a $120.1 million private placement at $56.00 per share and roughly 6.7 million shares issued for the acquisitions, lifting shares outstanding about 16% year-to-date to 49.3 million.
Key figures
- Revenue
- 194569000
- Total Debt
- 72935000
- Revenue Yoy
- Q3 product sales +64% YoY ($194.6M vs $118.7M); 9M total revenue $530.5M vs $299.7M
- Total Assets
- 505499000
- Cash Position
- 136530000
- Shares Outstanding
- 49303413
- Irenix upfront
- 35.2M cash + 607,093 shares ($40.7M)
- Irenix milestones
- up to $115M regulatory + $375M commercial
- Acquired iprd expense
- 632176000
- Marketable securities
- 173082000
- Q3 2025 product sales
- 118697000
- Q3 2026 product sales
- 194569000
- Customer concentration
- one customer 69.7% of Q3 gross product sales
- Nine month total revenue
- 530535000
- Alkeus regulatory milestone
- 250000000
- Nine month operating cash flow
- 30569000
- Private placement net proceeds
- 120100000
- Contingent consideration balance
- 85689000
- Alkeus acquisition total consideration
- 577269000
- Alkeus first commercial sale milestone
- 100000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.